Clorazepate News
Mylan Says It Will Appeal Court Decision In Last Of Lorazepam And Clorazepate Antitrust Cases
Friday, Mylan Inc. (MYL), a developer of Pharmaceutical ingredients, said that it intends to appeal a decision by the U.S. District Court for the District of Columbia on January 24, 2008 against the company and its co- defendants...
The twin effects of anxiety and fear
"Our fear is keeping the drug industry booming," so stated the Reverend Dr Robert Thompson, Suffragan Bishop of Kingston in a recent sermon. In a thought-provoking discourse, the bishop spoke about the booming sales of...
Virtual reality to the rescue
Therapists are turning to technology to help people overcome their deepest fears and anxieties
Trial Victory in Lorazepam and Clorazepate Antitrust Litigation
Analysis Group Managing Principal Atanu Saha provided expert testimony on liability and damages issues in recent antitrust litigation involving generic drug manufacturer Mylan.
Ranbaxy Receives USFDA Approval to Market Clorazepate Dipotassium Tablets USP
Ranbaxy Laboratories Limited (Ranbaxy) announced today that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Clorazepate Dipotassium Tablets USP, 3.75 mg, 7.5 mg, and 15 mg.